Journal
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Volume 202, Issue -, Pages 539-557Publisher
ELSEVIER
DOI: 10.1016/j.ijbiomac.2022.01.113
Keywords
Platelet-derived growth factor; PDGF; PDGFR signaling; Tumor therapy; Small molecule inhibitor; Clinical trial
Funding
- National Natural Science Foundation of China [82070469, 81770463, 81102858]
- Key Research and Development Guidance Project of Heilongjiang Province [GZ20210110]
- Heilongjiang Postdoctoral Science Foundation [LBH-Q16130]
- Youth Academic Backbone Support Program of Harbin University of Commerce [2020CX11]
- Graduate student innovation fund of Harbin University of Commerce [YJSCX2020-681HSD]
Ask authors/readers for more resources
The PDGF/PDGFR signaling pathway plays a crucial role in cancer, and targeting this pathway has become an effective strategy for cancer therapy with some progress in related research.
Platelet-derived growth factors (PDGFs) and PDGF receptors (PDGFRs) are expressed in a variety of tumors. Activation of the PDGF/PDGFR signaling pathway is associated with cancer proliferation, metastasis, invasion, and angiogenesis through modulating multiple downstream pathways, including phosphatidylinositol 3 kinase/ protein kinase B pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Therefore, targeting PDGF/PDGFR signaling pathway has been demonstrated to be an effective strategy for cancer therapy, and accordingly, some great progress has been made in this field in the past few decades. This review will focus on the PDGF isoforms and their binding with the related PDGFRs, the PDGF/PDGFR signaling and regulation, and especially present strategies and inhibitors developed for cancer therapy, and the related clinical benefits and side effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available